AR063057A1 - Metodo de inmunizacion contra los 4 serotipos de dengue - Google Patents

Metodo de inmunizacion contra los 4 serotipos de dengue

Info

Publication number
AR063057A1
AR063057A1 ARP070104316A ARP070104316A AR063057A1 AR 063057 A1 AR063057 A1 AR 063057A1 AR P070104316 A ARP070104316 A AR P070104316A AR P070104316 A ARP070104316 A AR P070104316A AR 063057 A1 AR063057 A1 AR 063057A1
Authority
AR
Argentina
Prior art keywords
dose
series
dengue virus
immunization method
dengue serotypes
Prior art date
Application number
ARP070104316A
Other languages
English (en)
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of AR063057A1 publication Critical patent/AR063057A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a un método para inducir proteccion contra los 4 serotipos de dengue en un paciente, que comprende: (a) una primera serie de administraciones (i) de una dosis de un virus de dengue para vacuna de un primer serotipo y de una dosis de un virus de dengue para vacuna de un segundo serotipo, y (ii) de una dosis de un virus de dengue para vacuna de un tercer serotipo y de una dosis de un virus de dengue para vacuna de un cuarto serotipo, y (b) una segunda serie de administraciones de dosis (i) y (ii), en donde las dosis (i) y (ii) se administran simultáneamente en distintos sitios anatomicos, y en donde la segunda serie se implementa al menos 30 días hasta como máximo 12 meses después de la primera serie.
ARP070104316A 2006-10-04 2007-09-28 Metodo de inmunizacion contra los 4 serotipos de dengue AR063057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.

Publications (1)

Publication Number Publication Date
AR063057A1 true AR063057A1 (es) 2008-12-23

Family

ID=38222583

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104316A AR063057A1 (es) 2006-10-04 2007-09-28 Metodo de inmunizacion contra los 4 serotipos de dengue

Country Status (15)

Country Link
US (2) US7718358B2 (es)
EP (3) EP2077857B1 (es)
JP (1) JP5269796B2 (es)
KR (1) KR20090064593A (es)
CN (2) CN101553251B (es)
AR (1) AR063057A1 (es)
AU (1) AU2007311792B2 (es)
BR (1) BRPI0719849A2 (es)
CA (1) CA2663885A1 (es)
FR (1) FR2906724B1 (es)
IL (2) IL197768A0 (es)
MX (1) MX2009003417A (es)
TW (2) TWI406673B (es)
WO (1) WO2008047023A2 (es)
ZA (1) ZA200901816B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
BRPI0909820A2 (pt) 2008-03-05 2015-08-11 Sanofi Pasteur Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
NZ597000A (en) * 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
EP2473624B1 (en) 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
BR112013032421A2 (pt) * 2011-06-29 2017-01-17 Immunotope Inc método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue
JP2015520196A (ja) * 2012-06-10 2015-07-16 タケダ ワクチン，インコーポレイテッドＴａｋｅｄａ Ｖａｃｃｉｎｅｓ，Ｉｎｃ． デングウイルスに対するワクチン投与のための組成物および方法
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
EP3932422A1 (en) * 2012-07-24 2022-01-05 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
MX2015000446A (es) 2012-07-24 2015-03-12 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
EP2931310A4 (en) * 2012-12-14 2016-05-25 Takeda Vaccines Inc COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
MY187896A (en) 2013-06-21 2021-10-27 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
MY192543A (en) 2014-12-22 2022-08-26 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
WO2017005652A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10655110B2 (en) * 2015-11-27 2020-05-19 Km Biologics Co., Ltd. Multivalent dengue vaccine composition comprising a mixture of attenuated dengue viruses from different serotypes
AU2018346724A1 (en) 2017-10-05 2020-05-14 Sanofi Pasteur Compositions for booster vaccination against dengu
IL281177B2 (en) 2018-09-05 2024-03-01 Takeda Vaccines Inc Dengue fever vaccine unit dose and its administration
MX2022001742A (es) 2019-08-16 2022-04-07 Takeda Vaccines Inc Metodos para prevenir el dengue y la hepatitis a.
US20240076631A2 (en) 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4375381A1 (en) 2022-11-18 2024-05-29 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP0977587B1 (en) 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
WO2000057908A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research, Department Of The Army Attenuated dengue-1 virus vaccine
US6511667B1 (en) 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
JP2002540166A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱３型ウイルスワクチン
WO2000057910A1 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
MXPA01009683A (es) * 1999-03-26 2003-06-24 Army Vacuna multivalente del virus del dengue.
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
ATE526411T1 (de) 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
DK1159968T3 (da) * 2000-05-30 2009-02-23 Univ Mahidol Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
EP2292802B1 (en) 2001-05-22 2015-01-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
KR100921592B1 (ko) 2001-06-01 2009-10-14 사노피 파스테르 바이오로직스 씨오 키메라 플라비바이러스 벡터
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
BRPI0306905B8 (pt) * 2002-01-15 2021-05-25 Acambis Inc método de produção de uma composição imunogênica/dengue que compreende um flavivírus
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
RU2343195C2 (ru) * 2003-03-24 2009-01-10 Дзе Скриппс Рисерч Инститьют Днк-вакцины против опухолевого роста и способы их применения
AU2006257610B2 (en) * 2005-06-17 2012-11-15 Centers For Disease Control And Prevention Dengue serotype 1 attenuated strain
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Also Published As

Publication number Publication date
BRPI0719849A2 (pt) 2014-04-29
WO2008047023A2 (fr) 2008-04-24
IL224572A (en) 2014-06-30
CN101553251B (zh) 2013-05-22
EP2077857B1 (fr) 2013-11-20
TW201336508A (zh) 2013-09-16
IL197768A0 (en) 2011-08-01
EP2526964A1 (fr) 2012-11-28
EP2077857A2 (fr) 2009-07-15
JP2010505801A (ja) 2010-02-25
US20080085288A1 (en) 2008-04-10
CN101553251A (zh) 2009-10-07
FR2906724B1 (fr) 2009-03-20
ZA200901816B (en) 2010-06-30
US20100270202A1 (en) 2010-10-28
JP5269796B2 (ja) 2013-08-21
CN103285386A (zh) 2013-09-11
WO2008047023A3 (fr) 2008-10-23
TWI406673B (zh) 2013-09-01
FR2906724A1 (fr) 2008-04-11
MX2009003417A (es) 2009-04-09
US7718358B2 (en) 2010-05-18
AU2007311792A1 (en) 2008-04-24
KR20090064593A (ko) 2009-06-19
EP2526965A1 (fr) 2012-11-28
AU2007311792B2 (en) 2013-05-02
TW200826959A (en) 2008-07-01
CA2663885A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
AR063057A1 (es) Metodo de inmunizacion contra los 4 serotipos de dengue
MY169275A (en) Method of immunization against the four serotypes of dengue
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
CY1123162T1 (el) Ελεγχομενης αποδεσμευσης φαρμακευτικα σκευασματα νιταζοξανιδης
ECSP099792A (es) Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
PH12014501133A1 (en) Compositions and methods for treating hepatitis c virus
ECSP099780A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c
CU20100203A7 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de la hepatitis c
BR112012022676A2 (pt) composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit
CR10669A (es) Vacuna
NI201200139A (es) Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales.
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
BR112014001798A2 (pt) compostos de tetraciclina 9-aminometila substituídos
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
WO2013104995A3 (en) Compositions and methods for treating viral infections
CO6280408A2 (es) Vacuna de virus de la lengua azul y composiciones inmunogenicas procedimientos de uso y procedimeintos de la produccuion de la misma
WO2010129947A3 (en) Alpha thymosin peptides as vaccine enhancers
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
NO20090290L (no) Polyvalent vaksine mot salmonid alfavirusinfeksjoner
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
AR040287A1 (es) Plataforma para formulaciones transdermicas (pft)
MX2022001742A (es) Metodos para prevenir el dengue y la hepatitis a.

Legal Events

Date Code Title Description
FB Suspension of granting procedure